SWE ORPHAN BIOVITRU (B6E BE) stock market data APIs
€35.1819
0.34(1%)
as of March 18, 2026
Try our APIs with
free plan!
SWE ORPHAN BIOVITRU Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for B6E.BE.
Prev. Close
35.1819
Open
35.5177
High
35.5555
Low
35.1538
52 wk Range
23.02-36.56
Market Cap
5 414 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SWE ORPHAN BIOVITRU data using free add-ons & libraries
Get SWE ORPHAN BIOVITRU Fundamental Data
SWE ORPHAN BIOVITRU Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SWE ORPHAN BIOVITRU News
New
Sobi's 2025 annual revenue and adjusted EBITA margin exceed previous outlook
STOCKHOLM, Jan. 15, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) announces today that revenue and adjusted EBITA margin for the full year 2025 were higher than previou...
Invitation: Sobi's Q4 and FY 2025 report
STOCKHOLM, Jan. 14, 2026 /PRNewswire/ -- Sobi plans to publish its report for the fourth quarter and full year of 2025 on 5 February 2026 at 08:00 CET. Investors, analysts, and the media are invited ...
Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data
STOCKHOLM, Jan. 7, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for interferon-gamma (IFNγ)-driven s...
How New Catalysts Are Shifting the Narrative for Swedish Orphan Biovitrum Stock
Swedish Orphan Biovitrum's updated narrative now centers on a slightly higher fair value estimate of SEK 367.09, up from SEK 360.36, paired with a marginally higher discount rate of 5.34% that reflect...
Get SWE ORPHAN BIOVITRU fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
